DK1411962T3 - Terapi for pancreacancer med monoklonalt stof - Google Patents
Terapi for pancreacancer med monoklonalt stofInfo
- Publication number
- DK1411962T3 DK1411962T3 DK02726672T DK02726672T DK1411962T3 DK 1411962 T3 DK1411962 T3 DK 1411962T3 DK 02726672 T DK02726672 T DK 02726672T DK 02726672 T DK02726672 T DK 02726672T DK 1411962 T3 DK1411962 T3 DK 1411962T3
- Authority
- DK
- Denmark
- Prior art keywords
- pancreatic cancer
- cancer therapy
- monoclonal
- drug
- monoclonal drug
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Acoustics & Sound (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27628401P | 2001-03-15 | 2001-03-15 | |
| PCT/US2002/009193 WO2002074251A2 (en) | 2001-03-15 | 2002-03-15 | Monoclonal antibody therapy for pancreas cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1411962T3 true DK1411962T3 (da) | 2011-04-04 |
Family
ID=23056011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02726672T DK1411962T3 (da) | 2001-03-15 | 2002-03-15 | Terapi for pancreacancer med monoklonalt stof |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20060228363A1 (da) |
| EP (3) | EP2295064B1 (da) |
| JP (1) | JP2004537976A (da) |
| AT (1) | ATE495751T1 (da) |
| CA (1) | CA2441042A1 (da) |
| DE (1) | DE60238987D1 (da) |
| DK (1) | DK1411962T3 (da) |
| ES (2) | ES2619313T3 (da) |
| WO (1) | WO2002074251A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529849A (ja) | 2000-09-01 | 2004-09-30 | インターナショナル バイオイムン システムズ，インコーポレーテッド | 扁平上皮癌に対する特異的モノクローナル抗体の同定と開発 |
| DK1411962T3 (da) | 2001-03-15 | 2011-04-04 | Neogenix Oncology Inc | Terapi for pancreacancer med monoklonalt stof |
| CA2571743A1 (en) * | 2004-06-30 | 2006-01-12 | International Bioimmune Systems, Inc. | Humanized monoclonal antibody 31.1 as an anticancer agent |
| US8101179B2 (en) * | 2005-03-31 | 2012-01-24 | Biomedics Inc. | Anti-CD20 monoclonal antibody |
| AU2009291882A1 (en) * | 2008-09-09 | 2010-03-18 | Oregon Health & Science University | Monoclonal antibodies specific for pancreatic neoplasia cells |
| EP2585476A4 (en) | 2010-06-22 | 2014-01-22 | Neogenix Oncology Inc | ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER |
| CA2896723C (en) * | 2012-12-28 | 2024-02-13 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
| KR102131371B1 (ko) * | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
| CA2925099C (en) * | 2013-10-01 | 2023-04-04 | Toray Industries, Inc. | Method for detecting pancreatic tumor, antibodies, and kit for the detection of pancreatic tumor |
| US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| US10617262B2 (en) | 2016-09-28 | 2020-04-14 | San Jamar, Inc. | Cutting board systems |
| US10617261B2 (en) | 2016-09-28 | 2020-04-14 | San Jamar, Inc. | Cutting board systems |
| US10856699B2 (en) | 2017-05-10 | 2020-12-08 | Scott Jackson Collins | Cutting board |
| USD857468S1 (en) | 2018-05-02 | 2019-08-27 | San Jamar, Inc. | Cutting board |
| USD858224S1 (en) | 2018-05-02 | 2019-09-03 | Scott Jackson Collins | Cutting board |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4713352A (en) * | 1981-08-31 | 1987-12-15 | Sloan-Kettering Institute For Cancer Reseach | Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma |
| US4404350A (en) | 1982-07-07 | 1983-09-13 | General Electric Company | Silicone-imide copolymers and method for making |
| DE3379203D1 (en) | 1982-07-14 | 1989-03-23 | Battelle Development Corp | Method for producing cross-linked resin coatings on substrates |
| US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| ZA858371B (en) * | 1984-11-02 | 1987-03-25 | Oncogen | Monoclonal antibodies for human non-small cell lung carcinomas |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0279669B1 (en) * | 1987-02-19 | 1995-12-27 | Scripps Clinic And Research Foundation | Cell surface marker of human pancreatic carcinoma cells |
| US5212085A (en) * | 1987-12-09 | 1993-05-18 | The General Hospital Corporation | Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen |
| US5688657A (en) * | 1988-03-31 | 1997-11-18 | International Bio-Immune Systems, Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991009957A1 (en) | 1989-12-22 | 1991-07-11 | E.I. Du Pont De Nemours And Company | Site-specific recombination of dna in plant cells |
| CA2110799A1 (en) * | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| SE9102074D0 (sv) * | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| CA2075343A1 (en) * | 1991-08-06 | 1993-02-07 | Nahoko Sato | Monoclonal antibody and uses of the same |
| AU7333794A (en) * | 1993-08-02 | 1995-02-28 | Houston Biotechnology Incorporated | Single-chain immunotoxin compositions and methods for preventing secondary cataracts |
| US5665848A (en) * | 1996-05-20 | 1997-09-09 | Dow Corning Corporation | Crosslinkers for silazane polymers |
| US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| FR2813427B1 (fr) | 2000-08-25 | 2002-11-29 | St Microelectronics Sa | Circuit de commande d'une memoire dram |
| DK1411962T3 (da) * | 2001-03-15 | 2011-04-04 | Neogenix Oncology Inc | Terapi for pancreacancer med monoklonalt stof |
| EP1411952B1 (en) | 2001-06-29 | 2009-04-22 | Glykos Finland Oy | Use of at least one glycoinhibitor substance against infectious diseases |
| KR100466197B1 (ko) | 2002-07-18 | 2005-01-13 | 주식회사 하이닉스반도체 | 플래시 메모리 셀 및 그 제조방법 |
-
2002
- 2002-03-15 DK DK02726672T patent/DK1411962T3/da active
- 2002-03-15 JP JP2002572962A patent/JP2004537976A/ja active Pending
- 2002-03-15 EP EP10177880.1A patent/EP2295064B1/en not_active Expired - Lifetime
- 2002-03-15 ES ES10177880.1T patent/ES2619313T3/es not_active Expired - Lifetime
- 2002-03-15 ES ES02726672T patent/ES2358977T3/es not_active Expired - Lifetime
- 2002-03-15 WO PCT/US2002/009193 patent/WO2002074251A2/en active Application Filing
- 2002-03-15 EP EP16204333.5A patent/EP3202790A1/en not_active Withdrawn
- 2002-03-15 AT AT02726672T patent/ATE495751T1/de not_active IP Right Cessation
- 2002-03-15 CA CA002441042A patent/CA2441042A1/en not_active Abandoned
- 2002-03-15 EP EP20020726672 patent/EP1411962B1/en not_active Expired - Lifetime
- 2002-03-15 DE DE60238987T patent/DE60238987D1/de not_active Expired - Lifetime
-
2005
- 2005-09-22 US US11/234,645 patent/US20060228363A1/en not_active Abandoned
-
2011
- 2011-01-21 US US13/011,631 patent/US9034588B2/en active Active
- 2011-01-21 US US13/011,485 patent/US8470326B2/en not_active Expired - Lifetime
-
2014
- 2014-10-08 US US14/509,428 patent/US9592290B2/en not_active Expired - Lifetime
-
2017
- 2017-01-27 US US15/417,326 patent/US20170210816A1/en not_active Abandoned
-
2018
- 2018-10-17 US US16/162,731 patent/US11001641B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2619313T3 (es) | 2017-06-26 |
| EP3202790A1 (en) | 2017-08-09 |
| EP2295064A1 (en) | 2011-03-16 |
| US20150104464A1 (en) | 2015-04-16 |
| WO2002074251A2 (en) | 2002-09-26 |
| US20060228363A1 (en) | 2006-10-12 |
| US9592290B2 (en) | 2017-03-14 |
| ES2358977T3 (es) | 2011-05-17 |
| US8470326B2 (en) | 2013-06-25 |
| EP1411962A4 (en) | 2005-02-02 |
| US11001641B2 (en) | 2021-05-11 |
| US20190100601A1 (en) | 2019-04-04 |
| US20120034227A1 (en) | 2012-02-09 |
| US20170210816A1 (en) | 2017-07-27 |
| ATE495751T1 (de) | 2011-02-15 |
| DE60238987D1 (de) | 2011-03-03 |
| EP1411962A2 (en) | 2004-04-28 |
| WO2002074251A3 (en) | 2004-02-19 |
| US9034588B2 (en) | 2015-05-19 |
| EP2295064B1 (en) | 2017-02-22 |
| EP1411962B1 (en) | 2011-01-19 |
| WO2002074251A9 (en) | 2004-05-06 |
| CA2441042A1 (en) | 2002-09-26 |
| JP2004537976A (ja) | 2004-12-24 |
| US20110165599A1 (en) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113224T1 (el) | Νεο αντισωμα αντι-ρlgf | |
| DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
| DK1385864T3 (da) | Anti-VEGF-2-antistoffer | |
| LU93274I2 (fr) | Elotuzumab | |
| HK1094167A1 (en) | Monoclonal antibodies to hepatocyte growth factor | |
| ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| PL401886A1 (pl) | Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal | |
| DK1210115T3 (da) | Doseringer til behandling med anti-ErB2-antistoffer | |
| DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
| CY1112229T1 (el) | Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β | |
| BRPI0414513A (pt) | kid3 e anticorpos de kid3 que se ligam a ele | |
| SG148190A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer | |
| DE60208534D1 (de) | Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle |